Xiong et al. revealed that anakinra blocked NLRP3 inflammasome-dependent pyroptosis, finally decreasing the death of mice infected with SASR-CoV-2.107 Canakinumab, the human monoclonal antibody targeting IL‐1β, is the effective treatment option for mild or severe non-ICU adult COVID-19 inpatients. This evidence concerns the gene IL1B and COVID-19.